D. Kukis

发表

Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals

D. Kukis, Min Li, C. Meares, 1993 .

A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging.

Katherine W Ferrara, J. Seo, K. Ferrara, 2008, Bioconjugate chemistry.

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

S Shen, G L DeNardo, K. Lamborn, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates

G. Denardo, S. Denardo, D. Kukis, 1994, Cancer.

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.

G. Denardo, S. Denardo, L. Miers, 1995, Cancer research.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.

S. Denardo, L. Miers, D. Kukis, 1995, Cancer research.

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.

G. Denardo, S. Denardo, S. Shen, 1997, Anticancer research.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

K. Lamborn, G. Denardo, S. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and Biodistribution of a Human Monoclonal Antibody to Oxidized LDL in Cynomolgus Monkey Using PET Imaging

S. Cherry, S. Rendig, C. Griesemer, 2012, PloS one.

Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

G. Denardo, S. Denardo, D. Kukis, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3)

G. Denardo, S. Denardo, S. Shen, 1994, Cancer.

A Smart and Versatile Theranostic Nanomedicine Platform based on Nanoporphyrin

Simon R. Cherry, Kit S. Lam, Sebastian Wachsmann-Hogiu, 2014, Nature Communications.

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6

K. Lamborn, G. Denardo, S. Denardo, 2002, The Prostate.

Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)

Yiyun Huang, H. Benveniste, R. Carson, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol.

E. Perez, K. Lamborn, G. Denardo, 1998, Anticancer research.

67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Copper-2-Iminothiolane-6-[ p-( Bromoacetamido ) benzyl ]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin ' s Lymphoma

S. Shen, D. Kukis, A. Yuan, 2007 .

Combined modality radioimmunotherapy

G. Denardo, S. Denardo, L. Miers, 2002, Cancer.

Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo.

S. Denardo, D. Kukis, C. Meares, 1992, Bioconjugate chemistry.

67 Cu- versus 131 I-Labeled Lym-1 Antibody: Comparative Pharmacokinetics and Dosimetry in Patients with Non-Hodgkin’s Lymphoma 1

G. Denardo, S. Denardo, S. Shen, 1999 .

Strategies for enhancement of radioimmunotherapy.

G. Denardo, S. Denardo, D. Kukis, 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Macrocyclic chelates of radiometals for diagnosis and therapy.

S. Denardo, D. Kukis, C. Meares, 1990, The British journal of cancer. Supplement.

Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer

G. Denardo, S. Denardo, S. Shen, 2001 .

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

F. Meyers, G. Denardo, S. Denardo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.

D. Kukis, C. Meares, N. Watanabe, 1994, Cancer research.

Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

S. Shen, D. Kukis, A. Yuan, 2007 .

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

K. Lamborn, G. Denardo, S. Denardo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.

Sven H. Hausner, J. Sutcliffe, D. Kukis, 2009, Molecular imaging.

Enhancement of 67Cu‐2IT‐BAT‐LYM‐1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin‐2

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation.

S. Cherry, G. Mitchell, T. Aweda, 2011, Bioconjugate chemistry.

Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.

G. Denardo, S. Denardo, S. Shen, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Anticancer research.

Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)

Yiyun Huang, H. Benveniste, R. Carson, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator.

G. Denardo, S. Denardo, S. Shen, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts

C. Abbey, J. Sutcliffe, D. Kukis, 2009, Molecular Imaging and Biology.

Effects of pair bonding on dopamine D1 receptors in monogamous male titi monkeys (Callicebus cupreus)

S. Cherry, W. Mason, S. Mendoza, 2017, American journal of primatology.

Efficacy and toxicity of radioimmunotherapy with 90Y‐DOTA‐peptide‐ChL6 for PC3‐tumored mice

K. Lamborn, G. Denardo, S. Denardo, 2000, The Prostate.

Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.

G. Denardo, S. Denardo, S. Shen, 1999, Cancer biotherapy & radiopharmaceuticals.

Safety profile after prolonged C3 inhibition.

B. Nilsson, J. Lambris, R. Doot, 2018, Clinical immunology.

Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.

G. Denardo, S. Denardo, D. Kukis, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Chelates for Radioimmunodiagnosis and Therapy'

S. Denardo, L. Miers, D. Kukis, 2006 .

131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis.

B. Wessels, G. Denardo, S. Denardo, 2000, Cancer biotherapy & radiopharmaceuticals.

Persistent neuroinflammation and cognitive impairment in a rat model of acute diisopropylfluorophosphate intoxication

S. Cherry, D. Tancredi, B. Ford, 2016, Journal of Neuroinflammation.

Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications

D. Kukis, Dustin J. Hadley, K. Campbell, 2017, PloS one.

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

K. Lamborn, G. Denardo, L. Miers, 2003, Blood.

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.

G. Denardo, S. Denardo, L. Miers, 1998, Cancer biotherapy & radiopharmaceuticals.

Preliminary evidence of increased striatal dopamine in a nonhuman primate model of maternal immune activation

C. Carter, S. Cherry, T. Lesh, 2019, Translational Psychiatry.

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1997, Proceedings of the National Academy of Sciences of the United States of America.

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

K. Lamborn, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Clinical lymphoma.

Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer.

S. Denardo, D. Kukis, I Novak-Hofer, 2001, Cancer biotherapy & radiopharmaceuticals.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

G. Denardo, S. Shen, D. Kukis, 1999, Cancer biotherapy & radiopharmaceuticals.

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).

G. Denardo, S. Denardo, S. Shen, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging.

Benjamin R. Jarrett, Angelique Y Louie, A. Louie, 2008, Bioconjugate chemistry.

Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A Chelates for Targeted Positron Emission Tomography with an αvβ6-Specific Peptide

J. Sutcliffe, D. Kukis, C. Anderson, 2009 .

In-Vivo Biodistribution and Safety of 99mTc-LLP2A-HYNIC in Canine Non-Hodgkin Lymphoma

K. Lam, S. Denardo, E. Wisner, 2012, PloS one.

Initial investigation of three selective and potent small molecule oxytocin receptor PET ligands in New World monkeys.

Elizabeth O. Ahlers, L. Young, M. Goodman, 2016, Bioorganic & medicinal chemistry letters.

Safety profile after prolonged C3 inhibition.

John D Lambris, B. Nilsson, J. Lambris, 2018, Clinical immunology.

Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging.

Benjamin R. Jarrett, A. Louie, D. Kukis, 2008, Bioconjugate chemistry.

Radiolabeling Human Peripheral Blood Stem Cells for Positron Emission Tomography (PET) Imaging in Young Rhesus Monkeys

S. Cherry, D. Kukis, A. Tarantal, 2013, PloS one.